Entity

Time filter

Source Type

SANTA CLARA, CA, United States

Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 1.95M | Year: 2009

DESCRIPTION (provided by applicant): TB-FISH is Dual Probe Fluorescent In-Situ Hybridization assay for detecting and differentiating Mycobacterium tuberculosis complex (MTB) ribosomal RNA (rRNA) and Mycobacterium species (rRNA) on a SINGLE methanol fixed smear, prepared either from a culture or directly from a specimen. The assay uses MTB and Mycobacterium genus (M-Genus) specific probes labeled with different fluorescent dyes. The assay is simple, rapid and in-expensive (lt 5.00/test and a one time expense of ~ 1200 for filters). The assay consists of six steps - Smear preparation and fixation, pretreatment, hybridization, and washing, counterstaining and viewing the processed smear under a fluorescent microscope. MTB and Mycobacterium shall fluoresce with different colors under specific dual pass filters. The total assay time is about 2 hours. Specific Aims: Develop a simple, rapid and in-expensive TB-FISH test kit for culture confirmation and direct detection of MTB in sputum samples. The kit shall contain all the reagents and control smears. Tuberculosis is the disease of the poor. Over one-third of the world's population (mostly in Africa and Asia) is at risk. The only means of identification of MTB is by microscopic examination of acid-fast stained smears. Unfortunately the acid-fast smear lacks both sensitivity and specificity. We demonstrated in Phase I that the MTB-FISH assay sensitivity in pure culture is between 1000 to 10,000 cells/ml for all the MTB complex bacteria. Based on a clinical study performed on over 100 patient smears, the assay sensitivity was better than acid-fast stained smears. As compared to culture, the FISH assay sensitivity in smear positive samples is gt95% and between 40-67% in smear negative samples, with overall sensitivity gt 80%, The acid-fast smear sensitivity is around 60%. As compared to culture, the MTB assay has 100% specificity in cultures and sputum. Based on the Phase I studies, the FISH assay may provide the specificity equivalent to amplified DNA probe assays, and sensitivity better than acid-fast smears. In the industrialized nations, this test may be useful for individuals with pulmonary tuberculosis since they are highly infectious and require immediate isolation and initiation of antituberculosis therapy. Specific Aims for Phase II (1) Purchase microscopes and filters for Clinical Sites and MTb manufacturing department (2) Manufacture TB-FISH Kits and determine shelf-life of reagents. (3) Evaluate Analytical Performance - Sensitivity and Specificity (4) Perform Interference Study - Endogenous and Exogenous (5) Evaluate Assay Reproducibility (6) Evaluate Clinical Performance of the TB-FISH Assays at 4-6 sites. (7) Develop inexpensive Microscope for FISH assays. Proceeding to Phase III will be based on completing the clinical trials and demonstrating specificity of at least 95% and sensitivity equivalent to or better than acid-fast stained smear as compared to culture. Specific Aims for Phase III (1) Filing PMA. (2) Marketing. (3) Work with WHOM to obtain their stamp of approval. This will avoid long delays in approval of the tests in many countries. (4) Develop M. avium complex FISH assay for detecting and differentiating MAI complex from other mycobacteria on a SINGLE smear. PUBLIC HEALTH RELEVANCE: Culture is the gold standard. Unfortunately it can take anywhere from one week to 2 months. Amplified assays have reduced the time to detection and confirmation to less than 2 days. They are especially useful in individuals with pulmonary tuberculosis, since they are highly infectious and require immediate isolation and initiation of antituberculosis therapy. Most of the TB endemic world is also resource poor countries. Because of the cost of the amplified assays, they are of little or no use in the TB endemic world. Some don't even have culturing facilities. The only means of diagnosis is based on acid-fast staining of direct sputum smears that lacks sensitivity and specificity. Therefore, a test like TB-FISH assay with the following attributes would be very useful. 1. Can be performed directly on unprocessed sputum at room temperature. 2. Has specificity of amplified assays and sensitivity superior to direct acid-fast staining. 3. Does not require expensive equipment other than a microscope. 4. Cost less than lt 5.00 5. From time of receipt of sputum sample to result is less than 2 hours. Based on the feasibility study performed in Phase I, we would like get a FDA approval for the TB-FISH assay. Therefore, in Phase II we shall perform all the studies required by FDA for a PMA filing.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 885.32K | Year: 2014

DESCRIPTION (provided by applicant): Malaria can be a life-threatening disease, especially in children, if left untreated. According to WHO, 525,000 to 2.0 million African children die from Malaria every year. The current gold standard for diagnosis is examination of Giemsa stained smear by microscopy. However, when parasite levels are very low, or in mixed infections, the information obtained by examination of Giemsa stained smear by microscopy is limited. Under SBIR Phase II we have developed 3 kits, P-Genus, PF and PV FISH assay kits. These kits detect malaria parasites on blood smears prepared with a special reagent by Fluorescent in Situ Hybridization (FISH) technique, using specific fluorescent labeled DNA probes targeted to ribosomal RNA of viable parasites. P- Genus kit detects all species of Plasmodium. PF-FISH kit and PV-FISH kit detect and differentiate P. falciparum and P. vivax from other species of Plasmodium respectively, on any P-Genus screen positive blood sample. Since ribosomal RNA is


Patent
Id Fish Technology, Inc. | Date: 2015-02-13

This invention relates to novel nucleic acid probes and methods for detecting


Patent
Id Fish Technology, Inc. | Date: 2014-12-29

An integrated circuit that communicates with a host device via audio channels includes an interfacing circuit that receives and transmits analog signals on the audio channels. Such audio channels are designed for audio speakers and microphones and the interfacing circuit transmits digital data based on the received analog signals. The integrated circuit includes a processing device that is electrically coupled to the interfacing circuit. The processing device receives the digital data from the interfacing circuit and adjusts at least one parameter of the interfacing circuit based on the received digital data. The interfacing circuit receives the digital data from the processing device and transmits analog signals on at least one of the audio channels based on the at least one adjusted parameter.


Patent
Id Fish Technology, Inc. | Date: 2011-04-13

This invention relates to novel nucleic acid probes and methods for detecting

Discover hidden collaborations